Raymond James Financial Inc. acquired a new stake in VanEck Biotech ETF (NASDAQ:BBH – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 21,540 shares of the company’s stock, valued at approximately $3,381,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. SBI Securities Co. Ltd. acquired a new position in VanEck Biotech ETF in the fourth quarter valued at approximately $81,000. Commonwealth Retirement Investments LLC acquired a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $215,000. Strategic Financial Concepts LLC purchased a new position in shares of VanEck Biotech ETF in the 4th quarter valued at $3,828,000. Flagship Harbor Advisors LLC grew its position in shares of VanEck Biotech ETF by 12.1% in the 4th quarter. Flagship Harbor Advisors LLC now owns 1,984 shares of the company’s stock valued at $311,000 after buying an additional 214 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in VanEck Biotech ETF during the 4th quarter worth $481,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.
VanEck Biotech ETF Price Performance
NASDAQ BBH opened at $159.66 on Friday. The company has a fifty day moving average of $163.02 and a two-hundred day moving average of $166.74. The company has a market capitalization of $389.56 million, a PE ratio of 33.67 and a beta of 0.85. VanEck Biotech ETF has a 1 year low of $151.35 and a 1 year high of $183.64.
VanEck Biotech ETF Company Profile
The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.
Featured Articles
- Five stocks we like better than VanEck Biotech ETF
- Stock Sentiment Analysis: How it Works
- Penny Stock SurgePays Rises 70%: 1 Reason to Buy, 5 to Sell
- P/E Ratio Calculation: How to Assess Stocks
- Top 3 Beverage Stocks Pouring Out Profits
- What is a Dividend King?
- CarMax and Carvana: Steering the Used Car Market
Want to see what other hedge funds are holding BBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for VanEck Biotech ETF (NASDAQ:BBH – Free Report).
Receive News & Ratings for VanEck Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
